Hemovent successfully debuts ExtraCorporeal Life Support (ECLS) device from its Artificial Lung platform
Hemovent GmbH has received a positive feedback for its ECLS device at REANIMATE 4, one of the leading-edge endovascular resuscitation conferences, organized by the ED ECMO Project. This event marked the first-ever presentation of the final design for the first application of Hemovents artificial lung platform designed for a whole range of applications. This is the first integrated solution accommodating both gas and blood management.
ECLS is also referred to as ExtraCorporeal Membrane Oxygenation (ECMO): the establishment of an artificial external blood circuit with a portable pump and gas exchanger system either as a temporary “artificial lung” for patients whose lungs are so damaged they cannot perform their function, or as a temporary “life support system” where it takes over the heart function in case of acute heart failure.
Hemovent GmbH is an emerging medical device company which is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit, the world’s smallest and first self-contained fully portable system designed for both Heart and Lung (ECMO) Support.
CAUTION: The Hemovent ECMO/ ECLS System is under development and not approved for human use yet.
You can read the complete press release here.